Tags: Drug.
Ibalizumab (TMB-355 previously known as TNX-355) is a non-immunosuppressive monoclonal antibody that binds CD4 the primary receptor for HIV and inhibits the viral entry process. It is being investigated as an HIV entry inhibitor with the ability to block both CCR5- and CXCR4-tropic viruses and is currently undergoing a Phase II clinical trial with an estimated study completion date in December 2010.